U.S. FDA approves Celltrion's OMLYCLO® (omalizumab-igec) as the first and only biosimilar with interchangeability designation referencing XOLAIR®
Celltrion today announced the U.S. Food and Drug Administration (FDA) approved OMLYCLO® (omalizumab-igec) as the first and ...
Yonhap News English on MSN2h
Celltrion gets U.S. approval for allergic asthma biosimilar
The U.S. Food and Drug Administration (FDA) approved Celltrion's Omlyclo, a biosimilar drug to Xolair, for treatment of moderate to severe persistent asthma, chronic rhinosinusitis with nasal polyps ...
The Pharma Letter16h
The week in pharma: action, reaction and insight – week to March 7
Last week’s significant research news included positive new Phase III data on Tezspire in nasal polyps from Amgen and ...